<?xml version='1.0' encoding='utf-8'?>
<document id="19272536"><sentence text="Preclinical pharmacology of sugammadex."><entity charOffset="28-38" id="DDI-PubMed.19272536.s1.e0" text="sugammadex" /></sentence><sentence text="Since the introduction of nondepolarizing neuromuscular blocking agents, acetylcholinesterase inhibitors have been used to increase the speed of recovery from neuromuscular blockade" /><sentence text=" The major disadvantages of acetylcholinesterase inhibitors are their lack of activity against profound neuromuscular blockade and their activity outside the neuromuscular junction resulting in unwanted side effects, requiring cotreatment with a muscarinic antagonist" /><sentence text=" An alternative to acetylcholinesterase inhibitors is the encapsulating agent sugammadex"><entity charOffset="78-88" id="DDI-PubMed.19272536.s4.e0" text="sugammadex" /></sentence><sentence text=" This agent has been specifically designed to encapsulate the steroidal neuromuscular blocking agents rocuronium and vecuronium"><entity charOffset="102-112" id="DDI-PubMed.19272536.s5.e0" text="rocuronium" /><entity charOffset="117-127" id="DDI-PubMed.19272536.s5.e1" text="vecuronium" /><pair ddi="false" e1="DDI-PubMed.19272536.s5.e0" e2="DDI-PubMed.19272536.s5.e0" /><pair ddi="false" e1="DDI-PubMed.19272536.s5.e0" e2="DDI-PubMed.19272536.s5.e1" /></sentence><sentence text=" This review describes the effects of sugammadex in in vitro tissue and in vivo animal experiments"><entity charOffset="38-48" id="DDI-PubMed.19272536.s6.e0" text="sugammadex" /></sentence><sentence text=" The encapsulation approach allows reversal of any degree of neuromuscular blockade because the dose of sugammadex can be adjusted to encapsulate sufficient neuromuscular blocking molecules to cause effective reversal"><entity charOffset="104-114" id="DDI-PubMed.19272536.s7.e0" text="sugammadex" /></sentence><sentence text=" Because this interaction is a drug-drug interaction, reversal can be achieved very fast but is limited by the circulation time" /><sentence text=" Sugammadex is also effective against neuromuscular blockade under conditions with reduced acetylcholine release, which potentiate the action of neuromuscular blocking agents"><entity charOffset="1-11" id="DDI-PubMed.19272536.s9.e0" text="Sugammadex" /><entity charOffset="91-104" id="DDI-PubMed.19272536.s9.e1" text="acetylcholine" /><pair ddi="false" e1="DDI-PubMed.19272536.s9.e0" e2="DDI-PubMed.19272536.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19272536.s9.e0" e2="DDI-PubMed.19272536.s9.e1" /></sentence><sentence text=" Sugammadex does not cause cholinergic side effects, preventing the need of coadministration of muscarinic antagonists" /><sentence text=" Because of these properties, sugammadex has the potential to become a very useful drug for the management of neuromuscular blockade"><entity charOffset="30-40" id="DDI-PubMed.19272536.s11.e0" text="sugammadex" /></sentence><sentence text="" /></document>